A61P17/18

COMPOSITIONS COMPRISING COMBINATIONS OF COLLAGEN OR ELASTIN POLYPEPTIDES WITH ACTIVE INGREDIENTS AND METHODS OF USING SAME
20230364000 · 2023-11-16 ·

This disclosure provides compositions comprising a collagen polypeptide (e.g., a human type 21 collagen polypeptide or a truncate thereof) or an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof), and one or more active ingredient. This disclosure also provides compositions comprising an elastin polypeptide (e.g., a human elastin polypeptide or a truncate thereof) in combination with a collagen polypeptide or truncate thereof. This disclosure further provides formulations comprising said composition, such as personal care products. This disclosure further provides methods of using the compositions and formulations provided herein (e.g., for application to the skin and/or hair a subject).

Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
11801261 · 2023-10-31 · ·

Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
11801261 · 2023-10-31 · ·

Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Topical skin care formulations comprising plant extracts
11752089 · 2023-09-12 · ·

A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Ficus retusa ssp. nitida, wherein the composition reduces tyrosinase activity or melanin production in the skin.

USE OF A CELL CULTURE COMPOSITION FOR PROMOTING CELL GROWTH

The embodiments of the present disclosure provide a cell culture composition and a use thereof, and the cell culture composition includes a culture medium and mitochondria. The cell culture composition including mitochondria can promote cell growth and improve the function of the damaged or aged stem cells, thereby improving overall cell growth.

COMPOSITION COMPRISING MITOCHONDRIA AND USE THEREOF FOR REPAIRING CARTILAGE DAMAGE OR IMPROVING OSTEOARTHRITIS

The embodiments of the present disclosure provide a composition including mitochondria. By providing the mitochondria to cartilage, the composition can improve the mitochondrial function of the chondrocytes in the cartilage so as to increase the repair ability of the chondrocytes and repair the cartilage damage caused by aging of the chondrocytes, thereby achieving the purpose of treating osteoarthritis.

TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS
20220296496 · 2022-09-22 ·

A method comprising topically applying to skin a composition comprising an aqueous, alcoholic, or aqueous-alcoholic extract from Ipomoea batatas.

Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities

The present invention relates to a cosmetic and/or dermatological composition comprising in a physiologically acceptable medium at least one merocyanine derivative of formula (1) or (2) and/or its E,E-, E,Z- or Z,Z-geometrical isomer forms: comprising specific polar groups consisting of hydroxyl- and ether-functionalities. Another object of the present invention relates to a cosmetic process for controlling and/or improving the darkening of the skin under exposure to UV radiation and the homogeneity of the colour of the complexion which comprises the application onto the skin of a cosmetic composition as above defined. Another object of the present invention relates to a cosmetic process for protecting the keratinic materials and particularly the skin against photo-ageing which comprises the application onto the keratinic material of a cosmetic composition as above defined. ##STR00001##

Topical skin care formulations comprising plant extracts
11419810 · 2022-08-23 · ·

Disclosed is a method for treating skin. The method can include topically applying to skin a composition comprising an effective amount of an aqueous, alcoholic, aqueous-alcoholic, or oil-soluble extract from Condurango, wherein the Condurango extract reduces oxidation in the skin, reduces tumor necrosis factor alpha (TNF-α) activity in the skin, or reduces matrix metalloprotease (MMP) 3 activity in the skin.

Selective peptide antagonists
11462297 · 2022-10-04 · ·

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.